Actively Recruiting

Phase Not Applicable
Age: 18Years - 70Years
All Genders
ID06796764

COMBO Endoscopy Oropharyngeal Airway Reduces Hypoxia During Sedated Gastrointestinal Endoscopy in Obese Patients: A Multicenter, Randomized, Controlled Clinical Trial

Led by Zhejiang University · Updated on 2025-09-10

580

Participants Needed

3

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the COMBO Endoscopy Oropharyngeal Airway device to reduce hypoxia in obese patients undergoing gastrointestinal endoscopy with sedation using propofol. Hypoxia is a common problem during these procedures, especially among obese individuals. This trial is a multicenter, randomized, controlled clinical study led by Zhejiang University to assess the safety and effectiveness of this new device in this high-risk group. Participants are randomly assigned to one of two groups: one group uses the COMBO Endoscopy Oropharyngeal Airway for oxygenation, while the other group uses a regular nasal cannula. Both devices support oxygen delivery during endoscopy and sedation. The procedure duration is limited to 45 minutes, and the study focuses on patients with a BMI of 28 kg/m² or higher. During the hospital stay, which averages about two hours, participants will be monitored for episodes of hypoxia and respiratory depression. Researchers will assess oxygen saturation levels and follow patients throughout the procedure and recovery period. Safety and efficacy outcomes will be recorded, including the incidence of oxygen desaturation events. The study will continue until December 2025.

CONDITIONS

Brief Title

COMBO Endoscopy Oropharyngeal Airway Reduces Hypoxia During Sedated Gastrointestinal Endoscopy in Obese Patients: A Multicenter, Randomized, Controlled Clinical Trial

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 70 years
  • Body mass index (BMI) of 28 kg/m² or higher
  • ASA classification of I or II
  • Signed informed consent form
  • Undergoing gastrointestinal endoscopy or colonoscopy
  • Procedure duration expected to be 45 minutes or less
Not Eligible

You will not qualify if you...

  • Contraindications to oropharyngeal airway use, such as bleeding disorders or anatomical issues
  • Severe heart failure with exercise capacity under 4 metabolic equivalents (METs)
  • Severe kidney failure requiring dialysis
  • Severe liver dysfunction
  • Chronic obstructive pulmonary disease (COPD) or ongoing pulmonary conditions needing oxygen therapy
  • High intracranial pressure
  • Upper respiratory tract infections
  • Fever above 37.5°C
  • Pregnancy or breastfeeding
  • Allergic reactions to sedatives like propofol or medical equipment
  • Urgent surgery required
  • Multiple injuries (polytrauma)
  • Preoperative oxygen saturation below 95% on room air
  • BMI less than 28 kg/m²
  • History of substance abuse in past 2 years
  • History of mental or neurological disorders
  • Participation in other clinical trials
  • Deemed ineligible by researchers

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Implementation

Duration - Approximately 2 hours during hospital stay

Participants receive oxygenation using either the COMBO Endoscopy Oropharyngeal Airway or a regular nasal cannula during sedated gastrointestinal endoscopy or colonoscopy.

1 procedure visit (in-person)

Trial Site Locations

Total: 3 locations

1

The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China, 310000

Actively Recruiting

2

The Fourth Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China, 310000

Actively Recruiting

3

Zhejiang Cancer hospital

Hangzhou, Zhejiang, China, 310000

Actively Recruiting

Loading map...

Research Team

D

Diansan Su, Chief Physician

M

Mingxia Xu

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Similar Trials

Phase III Randomized Controlled Trial Comparing D2 Versus D3...

Gastric Cancer

Actively Recruiting

1 location

18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chem...

Esophageal Cancer

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here